SunAct Cancer Institute is excited to announce the start of Phase 2 clinical trials on a groundbreaking treatment called Gamma Delta T-cell therapy. This trial, conducted in collaboration with CytoMed, Singapore, aims to bring hope to patients with difficult-to-treat cancers such as brain cancer, breast cancer, lung cancer, cervical cancer, colon cancer, renal cancer, liver cancer, lymph node cancer and several others.
This is a cutting-edge cancer treatment that uses special immune cells called Gamma Delta T-Cells. These cells naturally fight cancer while protecting the healthy tissue. What makes this treatment unique is that it uses ready-made cells from donors, making it faster, easier, and less expensive compared to traditional therapies.
This trial marks a major collaboration between SunAct Cancer Institute in India and CytoMed, a leader in cancer treatments from Singapore. Together, they aim to offer world-class cancer care to patients in India.
SunAct stands out for world-class collaboration. It has partnership with CytoMed ensures access to advanced cancer treatment research.
It is focused on solid tumors. This trial tackles solid tumors, which are harder to treat compared to blood cancers. It offers accessible treatments. SunAct is committed to bringing advanced therapies to patients across India. It has an expert team. SunAct’s top oncologists and researchers work to turn scientific discoveries into real-life treatments.
“Our goal is to provide advanced and affordable cancer treatments to patients in India,” said Dr. (Prof) Vijay Patil, Founder of SunAct Cancer Institute. “Gamma Delta T-Cell therapy is a promising solution for solid tumors, and through this collaboration with CytoMed, we hope to improve the lives of many cancer patients,” he added.
CytoMed’s Chairman Peter Choo said, “CytoMed’s collaboration with SunAct is timely and complements our core focus of harnessing CytoMed’s proprietary off-the-shelf technologies to develop novel donor-derived cell-based allogenic immunotherapies for the treatment of various cancers at affordable cost. We are aligned with the foresight of our partner SunAct to provide affordable no-option cancer therapeutics and are excited to work with Dr. Vijay Patil in our strive to accelerate the therapeutic application of CytoMed’s patented allogenic gamma delta T-Cells in, an increasing population of cancer patients in India and around the world.”
The trial will begin in early 2025, and patients will soon be able to enroll. All candidates will be carefully screened to ensure safety. For more information about the trial and how to enroll, please contact +91 86553 13412.
SunAct Cancer Institute is a leading center for advanced cancer research and treatment. By combining innovation and excellence, the institute aims to transform cancer care in India and beyond.
CytoMed, based in Singapore, specializes in cellular therapies for cancer and immune disorders. Their cutting-edge technology places them at the forefront of cancer treatment innovation.
No comments:
Post a Comment